Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

January 6, 2023

Spruce Biosciences, Kaken Pharmaceutical sign deal for tildacerfont to treat CAH

Spruce Biosciences and Kaken Pharmaceutical have signed an exclusive licensing agreement for the development and commercialisation of Spruce’s product candidate, tildacerfont, to treat congenial adrenal hyperplasia (CAH) in Japan.

Spruce Biosciences, Kaken Pharmaceutical sign deal for tildacerfont to treat CAH